To explore the optimal cutoff value of anti-PLA2R antibody to diagnose MN, we included 328 biopsy-proven MN patients and 232 biopsy-proven non-MN patients (96 IgAN patients, 80 MCD patients, 22 FSGS patients, 34 DN patients). Here, PLA2R1 is linked to focal segmental glomerulosclerosis.